- |||||||||| dexamethasone / Generic mfg.
Journal: Neutrophil extracellular traps may have a dual role in Pseudomonas aeruginosa keratitis. (Pubmed Central) - Jun 2, 2021
Cumulatively, our data suggest that NETs may play a dual role of infection control and corneal damage in P. aeruginosa keratitis. Furthermore, combination treatment targeting NET formation and bacteria may serve as a way of improving the clinical outcomes of bacterial keratitis.
- |||||||||| Tobradex (tobramycin/dexamethasone) / Alcon
[VIRTUAL] A Complex Case of Bilateral Diffuse Non-necrotizing Scleritis due to Rheumatoid Arthritis. (Track III - Academy at Home) - Oct 14, 2020 - Abstract #AAOPT2020AAOPT_870;
The patient was previously misdiagnosed with contact lens associated red eye (CLARE) in four prior eye exams and was treated with Tobradex...The case also outlined appropriate management of scleritis with steroids and topical anti-ocular hypertensive medications when the patient is a known steroid responder. Additionally, this case highlights the importance of ordering applicable lab work to uncover the underlying cause of the ocular condition, all while enlisting an interdisciplinary care team.
- |||||||||| Tobradex (tobramycin/dexamethasone) / Alcon
[VIRTUAL] Entire Day of Pain Needing a 4am Solution (Track 1 - Academy at Home) - Oct 14, 2020 - Abstract #AAOPT2020AAOPT_791;
It took 2 weeks for the rust ring to move anterior enough to attempt further removal. This case demonstrated determining the balance needed when considering future inflammatory responses with remaining rust ring and scarring.
- |||||||||| Tobradex (tobramycin/dexamethasone) / Alcon
[VIRTUAL] Diagnosis of Acanthamoeba Keratitis After Failed Presumed Herpes Simplex Keratitis Treatment (Track 1 - Academy at Home) - Oct 14, 2020 - Abstract #AAOPT2020AAOPT_617;
She had discontinued contact lens wear and tried Tobradex with minimal improvement that worsened after taper...Although the patient's eye is currently quiet after the recommended months of continued treatment, her vision remains reduced and she is scheduled next month for a Deep Anterior Lamellar Keratoplasty, which has been more effective in increasing the survival of transplanted corneal cells and to prevent entry of pathogenic organisms at the time of surgery. Conclusion This case is relevant because literature review reveals that proper early stage diagnosis is essential before it invades more deeply into the cornea, where it can cause permanent tissue damage. Unfortunately, this disease is more commonly diagnosed as HSV keratitis than AK.
- |||||||||| Tobradex (tobramycin/dexamethasone) / Alcon
[VIRTUAL] Epidemic Keratoconjunctivitis in a Time of COVID-19 (Track 1 - Academy at Home) - Oct 14, 2020 - Abstract #AAOPT2020AAOPT_607;
Denies anyone at party having pink eye.Medical history only remarkable for ear infection occurring one-month prior with resolution. No medications. Pertinent Findings Unless otherwise stated findings were unremarkableInitial Visit:scVA: 20/70 OD, 20/40-2 OS; PH 20/40 OD, 20/30 OSLids/Lashes: trace edema and redness ODConjunctiva/Sclera: OD 1+ injection, pseudomembrane superior, giant papillae; OS 1+ injection, 3+ papillaeCornea: OD 5x3mm erosion superior; OS trace SPKDay 2:scVA: 20/80 OD, 20/50 OSLids/Lashes: Moderate lid edema and erythema OUConjunctiva/Sclera: OD 2+ injection with pseudomembrane superior, 3+ follicles upper and lower lid; OS same as OD but no pseudomembraneCornea: OD 5x5mm central erosion; OS subepithelial deposits superior limbusDay 4:scVA: 20/200 OD, 20/40 OSLids/Lashes: stable OUConjunctiva/Sclera: Stable with improved injection OU, pseudomembrane superior OSCornea: OD 2x3mm erosion nasal to visual axis and superior, re-epithelialization central, 1-2+ edema with endothelial folds; OS stable with addition of scattered peripheral epithelial erosionsDay 7:scVA: 20/30 OD, OS; PH 20/20-1 OD, OSLids/Lashes: Mild lid edema OUConjunctiva/Sclera: White and quiet bulbar conjunctiva, pseudomembrane superior, 2+ follicles upper and lower lid OD, OSCornea: Few scattered SPK OD, OS Differential Diagnosis Primary: Epidemic Keratoconjunctivitis (EKC), Viral conjunctivitis with Covid-19 as etiologySecondary: Bacterial conjunctivitis Diagnosis and Discussion EKC typically presents with a history of upper respiratory tract infection or prior exposure to someone with viral conjunctivitis.1 A distinguishing feature of EKC is corneal involvement, including diffuse, fine epithelial keratitis that may progress to a corneal erosion in severe cases.1,2 Given history of crowd exposure, COVID-19 was considered as a possible etiology for this patient’s condition. Treatment, Management Initial visit:Erythromycin ung q6hr OD, ocuflox QID ODCOVID-19 PCR test ordered, quarantine until COVID-19 ruled outDay 2:Erythromycin ung every q2hr OD, ocuflox q1hr OD.In office pseudomembrane peel ODCOVID-19 test came back negativeDay 4:Pred Forte QID OU and erythromycin ung BID OU, PFATs q2hr or prnIn office pseudomembrane peel OU and Betadine wash OUDay 7:Pred Forte TID OU, PF ATs q2hr or prnIn office pseudomembrane peel OULost to follow up, ongoing attempts to contact patient Conclusion Pseudomembrane peel is vital in EKC due to risk to corneaBetadine wash essential to reducing viral load which may expedite resolutionBe aware of Covid-19 guidelines and testing in regards to seeing patients who present with a red eye
- |||||||||| Tobradex (tobramycin/dexamethasone) / Alcon
[VIRTUAL] Perplexing Papillae: A GPC Masquerader (Track 1 - Academy at Home) - Oct 14, 2020 - Abstract #AAOPT2020AAOPT_384;
Adjuvant therapies include cryotherapy, topical cytotoxic drops and radiotherapy. Conclusion It is important to account for systemic health when making diagnoses of ocular surface lesions. Moreover, unilateral chronic conjunctivitis, which does not improve with treatment warrants consideration of SCC as a masquerader.
- |||||||||| Tobradex (tobramycin/dexamethasone) / Alcon
[VIRTUAL] Corneal Ulcers: Treatment and Alternative Therapy for Functional Vision (Track 1 - Academy at Home) - Oct 14, 2020 - Abstract #AAOPT2020AAOPT_121;
A prescription of +12.00D 14pd BI in OD, OS was prescribed for spot reading and MaxTV clip for TV viewing. Conclusion Not all aggressive treatments can be successful as residual scarring can form and impact vision. Functional vision can be temporarily “restored” to an extent with alternative therapies like specialty contact lenses and use of low vision devices.
- |||||||||| Tobradex (tobramycin/dexamethasone) / Alcon
[VIRTUAL] Viral Conjunctivitis With Probable Association With The Novel Coronavirus Disease 2019 (Track 1 - Academy at Home) - Oct 14, 2020 - Abstract #AAOPT2020AAOPT_47;
Still, the SEIs remained stable and scarring ensured.SEI’s may last for months to years even after the infection subsides and can scar and affect vision.1 At this point, we are managing the corneal scars and refractive error. Conclusion Given the COVID-19 pandemic, there has been reports in the literature regarding conjunctivitis associated with COVID-19 with a similar presentation to our patient. 2 This case report emphasizes and agrees that we should not dismiss that viral conjunctivitis can arise from COVID-19.
- |||||||||| Tobradex (tobramycin/dexamethasone) / Alcon, acetazolamide / Generic mfg.
[VIRTUAL] Blindness is not the end () - Sep 23, 2020 - Abstract #ESCRS2020ESCRS_1369;
However, this case report reminds us that it is important to assess the ophthalmological patient beyond his VA, since we could probably have prevented the development of the corneal damage. It is important for a patient like the one described to continue under ophthalmological follow-up due to the risk of complications that may arise.
- |||||||||| Tobradex (tobramycin/dexamethasone) / Alcon, prednisone / Generic mfg., Durezol (difluprednate ophthalmic emulsion) / Senju, Novartis
[VIRTUAL] Bisphosphonate Related Ocular Inflammation () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_692;
She was also advised to apply Durezol eye drops twice a day...While considering bisphosphonates as an option for osteoporosis treatment, the endocrinologist should discuss the rare but serious complications of BROI. With use of bisphosphonates in the aging population to treat osteoporosis, specific attention should be given to underlying eye disease, inflammatory conditions, and cognition.
- |||||||||| tobramycin/dexamethasone / Generic mfg.
Trial completion: Probiotics for Chalaziosis Treatment in Children (clinicaltrials.gov) - Apr 23, 2020
P=N/A, N=26, Completed,
With use of bisphosphonates in the aging population to treat osteoporosis, specific attention should be given to underlying eye disease, inflammatory conditions, and cognition. Active, not recruiting --> Completed
- |||||||||| Tobradex (tobramycin/dexamethasone) / Alcon, prednisone / Generic mfg., Durezol (difluprednate ophthalmic emulsion) / Senju, Novartis
Bisphosphonate Related Ocular Inflammation (ENDOExpo) - Apr 1, 2020 - Abstract #ENDO2020ENDO_4210;
She was also advised to apply Durezol eye drops twice a day...While considering bisphosphonates as an option for osteoporosis treatment, the endocrinologist should discuss the rare but serious complications of BROI. With use of bisphosphonates in the aging population to treat osteoporosis, specific attention should be given to underlying eye disease, inflammatory conditions, and cognition.
- |||||||||| NN1213 / Novo Nordisk
Enrollment closed, Trial primary completion date: VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia (clinicaltrials.gov) - Feb 25, 2020
P=N/A, N=187, Active, not recruiting,
With use of bisphosphonates in the aging population to treat osteoporosis, specific attention should be given to underlying eye disease, inflammatory conditions, and cognition. Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2019 --> Sep 2020
- |||||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron
Influence of intravitreal aflibercept on diabetic macular oedema after phacoemulsification () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_731;
Uncomplicated phacoemulsification in diabetic patients with non-central DME may lead to formation of central-involved DME and this, in turn, can lead to a decrease in BCVA. The additional risk factors for of central-involved DME are worse initial visual acuity (<0.1), severe NPDR or PDR.Intravitreal aflibercept injection at the end of surgery may significantly reduce the risk of central-involved DME.
- |||||||||| Tobradex (tobramycin/dexamethasone) / Alcon, tropicamide / Generic Mfg.
Hospital Price Transparency Law Application Among 11 Large U.S. Ophthalmology Departments (Moscone Center EPOSTER & VIDEO TERMINALS) - Sep 5, 2019 - Abstract #AAO2019AAO_2357;
Furthermore, some data were not even reported. Conclusion Greater price transparency efforts are needed to ensure that patients are able to effectively compare costs of procedures and medications that they might require for their care.
- |||||||||| tobramycin/dexamethasone / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia (clinicaltrials.gov) - Jul 11, 2016
P=N/A, N=187, Recruiting,
Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Sep 2018 --> Sep 2019 Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Apr 2016 | Trial primary completion date: Sep 2017 --> Sep 2018
- |||||||||| tobramycin/dexamethasone / Generic mfg., levofloxacin / Generic mfg.
Trial completion, Trial primary completion date: Early Changes Among FLEx, LASIK and FS-LASIK (clinicaltrials.gov) - Jun 15, 2016
P=N/A, N=75, Completed,
Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Apr 2016 | Trial primary completion date: Sep 2017 --> Sep 2018 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2016
- |||||||||| tobramycin/dexamethasone / Generic mfg.
Trial completion, Trial primary completion date: Chalazion Conservative Treatment Trial (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=150, Completed,
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2016 Not yet recruiting --> Completed | Trial primary completion date: Nov 2012 --> Oct 2015
|
